February 9th 2015
BMG Pharma S.r.l. today is pleased to announce that it has obtained the inclusion of the Molluscum Contagiosum in the CE Mark certificate for the product named Ialuxid® Gel, already approved also for the treatment of acne lesions, folliculitis, paronychia, and impetigo.
Ialuxid® Gel shall allow patients to receive the best care possible by using our innovative delivery technology to eliminate Molluscum Contagiosum. This common viral disease has a higher incidence in children, sexually active adults, and those who are immuno-deficientand the infection is most common in children aged one to ten years old.
“BMG Pharma’s working team has been strongly committed in the invention and creation of major medical devices, and this is the first approach for our company to Molluscum Contagiosum in the device segment.
”We believe this is a short term improvement for the Product” – said Marco Mastrodonato, CEO of BMG Pharma S.r.l. – “We are pleased to offer such new indication to our current partners and provide opportunity for the territories where the product is still available for licensing”
Ialuxid ® GEL is a unique combination gel formulation which can be used to treat acne lesions, folliculitis, paronychia, Molluscum Contagiosum and impetigo. The key ingredients in this novel formulation – hyaluronic acid, glycine and hydrogen peroxide – it forms a protective film against external agents and prevents the bacterial infections due to the synergistic effects against a wide range of micro-organisms and to a protective and effective filmogenic barrier to the skin.
BMG Pharma S.r.l. is a specialty pharmaceutical company with head office in Milan, Italy, leveraging its proprietary technology to develop products that address unmet needs of patients. The Company is currently focused on cancer supportive care, dermatology gynecology, ENT and oral health. BMG Pharma S.r.l. is dedicated to helping patients, pharmacists and physicians by providing valuable and innovative products to the market.
The Company’s key features are:
Ø Full involvement in business and partnering
Ø Presence in different therapeutic areas
Ø Specific regulatory strategies for each product as Prescription and OTC Medical Devices in EC and US to allow rapid market introduction. BMG focuses on bringing products to market quickly with supportive clinical data.
Ø IP protection for most of the products and technologies.
For press releases and other company information, visit :